newsfilter
← Latest News
GlobeNewswire·

LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU Symposium

Favorable safety profile to date, with no occurrence of high-grade (>2) cytokine release syndrome or dose-limiting toxicitiesPreliminary signs of anti-tumor activity were observed, with iRECIST stable disease (iSD) in